BNP Paribas Financial Markets
LABD icon

BNP Paribas Financial Markets’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

BNP Paribas Financial Markets’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$816K Sell
50,064
-50,000
-50% -$946K ﹤0.01% 3275
2025
Q4 		$2.11M Sell
100,064
-25,706
-20% -$697K ﹤0.01% 2591
2025
Q3 		$5.06M Buy
+125,770
New +$7.29M ﹤0.01% 1971

Other funds holding LABD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Capstone Capital Management Hong Kong $224M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

BNP Paribas Financial Markets's LABD Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 50% in Q1 2026, selling an estimated $946K and leaving 50,064 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

BNP Paribas Financial Markets first reported a position in LABD in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.06M in Q3 2025. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

  • BNP Paribas Financial Markets held 50,064 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $816K as of Q1 2026.
  • BNP Paribas Financial Markets sold 50,000 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $946K.
  • Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3275 holding.
  • BNP Paribas Financial Markets first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2025 and has held it in 3 quarters since.
  • BNP Paribas Financial Markets's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $5.06M in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.